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Introduction
Recurrent pericarditis (RP) has a controversial pathogenesis
that crosses infectious, auto-immune and auto-inflammatory
pathways. It has been suggested that in some cases it might
be an unrecognized auto-inflammatory disease. Recent stu-
dies have demonstrated that anakinra, an interleukin-1
receptor antagonist (IL-1RA), represents an effective treat-
ment for the control of corticosteroid-dependent cases.
Objectives
Here we describe a case of cortico-dependent recurrent
pericarditis with a different response to two IL-1 blocking




A 11-year-old boy was admitted to our hospital with acute
precordial pain, orthopnea, fever and increased levels of
acute phase reactants. Acute pericarditis was confirmed by
echocardiography and a treatment with prednisone was
started with prompt clinical improvement. Pericarditis
recurred twice during steroid tapering (at 1mg/kg/day and
0.5mg/kg/day respectively). After exclusion of infectious
origin, therapy with anakinra (2mg/kg/day) was estab-
lished (to avoid long term steroid side effects) followed by
dramatic clinical response and normalisation of laboratory
findings despite tapering and discontinuation of predni-
sone. Treatment with anakinra was discontinued after 5
months with recurrence of pericarditis one week later.
Anakinra was resumed with an excellent response. Five
months later, while being in complete remission, anakinra
was replaced with canakinumab (2mg/kg/dose) due to
patient’s intolerance of daily injections. One week later,
the patient experienced a new episode of pericarditis
requiring corticotherapy. Two more relapses occured dur-
ing steroid tapering, after 6 weeks and 2 months, in spite
of the uptitration of canakinumab to 4mg/kg/dose. Ana-
kinra was restarted with prompt clinical and biological
remission and prednisone was discontinuated without
recurrence of pericarditis. Four weeks later, anakinra was
spaced out every 2 days and a treatment of colchicine was
added. After further 12 weeks follow-up under anakinra
and colchicine, the pericarditis is still in remission.
Conclusion
We describe a case of steroid-dependent RP with a dra-
matic therapeutic response to IL-1RA (anakinra) but
without response to IL-1b monoclonal antibody (canaki-
numab). This unexpected observation could suggest that
Il-1a might have a role in the pathogenesis of RP.
A more precise usefulness of each IL-1 blocking agent
requires confirmation in prospective controlled trials.
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